Results 41 to 50 of about 13,123 (252)

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO

BMC Cancer, 2021
The main reason for treatment failure after curative surgical resection of gastric cancer is intra-abdominal spread, with 40–50% peritoneal seeding as primary localization of recurrence.
T. Goetze, P. Piso, S. Lorenzen, U. Bankstahl, C. Pauligk, Moustafa Elshafei, G. Amato, D. Reim, W. Bechstein, A. Königsrainer, S. Mönig, B. Rau, M. Schwarzbach, S. Al-Batran   +13 more
semanticscholar   +1 more source

The Global End-Diastolic Volume (GEDV) Could Be More Appropiate to Fluid Management Than Central Venous Pressure (CVP) During Closed Hyperthermic Intrabdominal Chemotherapy with CO2 Circulation

Journal of Investigative Surgery, 2018
Background: Closed hyperthermic intraperitoneal chemotherapy (HIPEC) may increase abdominal pressure and effects of hemodynamic changes due to maintenance hyperthermia.
Francisco Javier Redondo, David Padilla, Pedro Villarejo, Victor Baladron, Patricia Faba, Sergio Sánchez, José Ramón Muñoz-Rodríguez, Natalia Bejarano   +7 more
doaj   +1 more source

Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial

International Journal of Gynecological Cancer, 2020
Background The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary cytoreductive ...
S. Koole, R. V. van Stein, K. Sikorska, D. Barton, L. Perrin, D. Brennan, O. Zivanovic, B. Mosgaard, A. Fagotti, Pierre-Emmanuel Colombo, G. Sonke, W. J. V. Driel   +11 more
semanticscholar   +1 more source

Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients

British Journal of Cancer, 2021
Patients with metastatic colorectal cancer (mCRC) carrying BRAF (mutBRAF) or KRAS mutation (mutKRAS) have an inferior prognosis after liver or lung surgery, whereas the prognostic role in the context of peritoneal metastasis (PM) after cytoreductive ...
S. Larsen, M. Goscinski, S. Dueland, S. Steigen, E. Hofsli, A. Torgunrud, M. Lund-Iversen, V. Dagenborg, K. Flatmark, H. Sørbye   +9 more
semanticscholar   +1 more source

HIPEC-Induced Acute Kidney Injury: A Retrospective Clinical Study and Preclinical Model

Annals of Surgical Oncology, 2021
Background Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery (CRS) is the treatment of choice for selected patients with peritoneal malignancies.
Lukas F. Liesenfeld, B. Wagner, H. Hillebrecht, M. Brune, C. Eckert, J. Klose, T. Schmidt, M. Büchler, Martin Schneider   +8 more
semanticscholar   +1 more source

Tumor Mutational Burden Associated With Response to Hyperthermic Intraperitoneal Chemotherapy

Frontiers in Oncology, 2022
BackgroundGastric cancer (GC) is one of the most common cancer types, especially in Asian countries. Hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to improve the progression-free survival among gastric cancer patients with peritoneal ...
Lisi Zeng, Xubo Huang, Yun Tian, Jinxia Huang, Huiyan Liu, Juncai Wen, Kaihua Liu, Yang Shao, Jiali Luo, Hongsheng Tang, Quanxing Liao, Ziying Lei, Weiwen Cui, Qianghua Xia, Tianpei Guan, Jin Li, Shuzhong Cui, Shuzhong Cui   +17 more
doaj   +1 more source

Dedicated MRI staging versus surgical staging of peritoneal metastases in colorectal cancer patients considered for CRS-HIPEC; the DISCO randomized multicenter trial

BMC Cancer, 2021
Background Selecting patients with peritoneal metastases from colorectal cancer (CRCPM) who might benefit from cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is challenging.
M. Engbersen, C. Rijsemus, J. Nederend, A. Aalbers, I. D. de Hingh, V. Retèl, D. Lambregts, E. V. D. van der Hoeven, D. Boerma, M. Wiezer, M. D. de Vries, E. Madsen, A. Brandt-Kerkhof, S. van Koeverden, P. D. de Reuver, R. Beets‐Tan, N. Kok, M. Lahaye   +17 more
semanticscholar   +1 more source

Efficacy of Cytoreductive Surgery (CRS) + HIPEC in Gastric Cancer with Peritoneal Metastasis: Systematic Review and Meta-Analysis

Cancers
Simple Summary Peritoneal disease in gastric cancer has a poor prognosis, with a median survival of 3–6 months and a 5-year survival rate of 0%. Despite multiple advancements in therapeutics, the National Comprehensive Cancer Network (NCCN) guidelines ...
L. Langellotti, C. Fiorillo, G. D’Annibale, Edoardo Panza, Fabio Pacelli, S. Alfieri, A. di Giorgio, F. Santullo   +7 more
semanticscholar   +1 more source

Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer

Cureus, 2021
Hyperthermic intraperitoneal chemotherapy (HIPEC), along with optimal cytoreductive surgery, has been debated to be a viable option for the treatment of advanced epithelial ovarian cancer with peritoneal carcinomatosis.
Mona Mishra, Nilanchali Singh, P. Ghatage   +2 more
semanticscholar   +1 more source

Readmissions after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy—a national population-based study

World Journal of Surgical Oncology, 2020
Background Comprehensive readmission morbidity studies after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are scarce. This study aimed to investigate readmissions and in-hospital morbidity after CRS and HIPEC. Methods
Paul Dranichnikov, Wilhelm Graf, Peter H. Cashin   +2 more
doaj   +1 more source